Estrogen receptor
From Proteopedia
(Difference between revisions)
Line 29: | Line 29: | ||
**[[2bj4]], [[2jf9]], [[2jfa]], [[1pcg]] - hERα LBD + peptide antagonist<br /> | **[[2bj4]], [[2jf9]], [[2jfa]], [[1pcg]] - hERα LBD + peptide antagonist<br /> | ||
**[[2yja]] - hERα LBD + stapled peptide<br /> | **[[2yja]] - hERα LBD + stapled peptide<br /> | ||
+ | **[[2q6j]], [[2p15]], [[3erd]], [[1l2i]] - hERα LBD + GRIP peptide<br /> | ||
**[[2yat]] - hERα LBD (mutant) + EST derivative<br /> | **[[2yat]] - hERα LBD (mutant) + EST derivative<br /> | ||
**[[3uuc]] - hERα LBD + bisphenol<br /> | **[[3uuc]] - hERα LBD + bisphenol<br /> | ||
+ | **[[3q97]] - hERα LBD + LXXLL motif (mutant) + ethoxy triphenylethylene<br /> | ||
+ | **[[1gwr]] - hERα LBD + TIF2 peptide + EST<br /> | ||
+ | **[[2ocf]] - hERα LBD (mutant) + fibronectin domain 10 + EST<br /> | ||
- | *''ERα LBD ternary complex with steroid receptor coactivator peptide'' | + | *''ERα LBD ternary complex with steroid receptor coactivator 1 peptide'' |
- | **[[ | + | **[[3uu7]], [[3uua]], [[3uud]] - hERα LBD (mutant) + nuclear receptor coactivator 1 peptide<br /> |
- | **[[ | + | **[[4dma]] - hERα LBD (mutant) + nuclear receptor coactivator 1 peptide + inhibitor<br /> |
- | **[[ | + | **[[4mg5]], [[4mg6]], [[4mg7]], [[4mg8]], [[4mg9]], [[4mga]], [[4mgb]], [[4mgc]], [[4mgd]] - hERα LBD (mutant) + nuclear receptor coactivator 1 peptide + ligand<br /> |
- | **[[ | + | **[[4tuz]] - hERα LBD (mutant) + steroid receptor coactivator 1 peptide + toxin<br /> |
- | **[[ | + | **[[4tv1]] - hERα LBD (mutant) + steroid receptor coactivator 1 peptide + preservative<br /> |
- | **[[2g5o]] - hERα LBD + nuclear receptor coactivator peptide + EST derivative<br /> | + | |
- | ** | + | *''ERα LBD ternary complex with steroid receptor coactivator 2 peptide'' |
- | **[[1gwq | + | |
- | **[[ | + | **[[2b23]] - hERα LBD (mutant) + nuclear receptor coactivator 2 peptide<br /> |
- | **[[ | + | **[[3q95]] - hERα LBD (mutant) + nuclear receptor coactivator 2 peptide + EST<br /> |
- | **[[ | + | **[[4iu7]], [[4iui]], [[4iv2]], [[4iv4]], [[4ivw]], [[4ivy]], [[4iw6]], [[4iw8]], [[4iwc]], [[4iwf]] - hERα LBD (mutant) + nuclear receptor coactivator 2 peptide + inhibitor<br /> |
- | **[[ | + | **[[2g5o]] - hERα LBD + nuclear receptor coactivator 2 peptide + EST derivative<br /> |
+ | **[[2qgt]] - hERα LBD (mutant) + nuclear receptor coactivator 2 peptide + EST derivative<br /> | ||
+ | **[[1gwq]], [[2fai]], [[2g44]], [[2qzo]] - hERα LBD + nuclear receptor coactivator 2 peptide + ligand<br /> | ||
+ | **[[3l03]], [[3hm1]], [[3hlv]], [[1zky]], [[2b1v]], [[2b1z]], [[2qa6]], [[2qab]], [[2qgw]], [[2qh6]], [[2qr9]], [[2qse]], [[2qxm]] - hERα LBD (mutant) + nuclear receptor coactivator 2 peptide + ligand<br /> | ||
+ | **[[2qa8]] - hERα LBD (mutant) + steroid receptor coactivator 2 peptide + genistein<br /> | ||
+ | **[[4pp6]], [[4ppp]], [[4pps]] - hERα LBD (mutant) + steroid receptor coactivator peptide 2 + resveratrol derivative<br /> | ||
+ | |||
+ | *''ERα LBD ternary complex with steroid receptor coactivator 3 peptide'' | ||
+ | |||
+ | **[[1x7r]] - hERα LBD + steroid receptor coactivator 3 peptide + genistein<br /> | ||
+ | **[[1x7e]] - hERα LBD + nuclear receptor coactivator 3 peptide + ligand<br /> | ||
*Estrogen receptor β ligand binding domain | *Estrogen receptor β ligand binding domain | ||
Line 54: | Line 68: | ||
**[[2yly]] - hERβ LBD + sulfonamide agonist<br /> | **[[2yly]] - hERβ LBD + sulfonamide agonist<br /> | ||
**[[2fsz]] - hERβ LBD (mutant) + ligand<br /> | **[[2fsz]] - hERβ LBD (mutant) + ligand<br /> | ||
- | **[[2yja]] - hERβ LBD + stapled peptide<br /> | + | **[[2yja]], [[2yjd]] - hERβ LBD + stapled peptide<br /> |
**[[4j24]], [[4j26]] - hERβ LBD + peptide<br /> | **[[4j24]], [[4j26]] - hERβ LBD + peptide<br /> | ||
Revision as of 10:07, 31 March 2015
|
3D structures of estrogen receptor
Updated on 31-March-2015
Reference
- ↑ Li MJ, Greenblatt HM, Dym O, Albeck S, Pais A, Gunanathan C, Milstein D, Degani H, Sussman JL. Structure of estradiol metal chelate and estrogen receptor complex: The basis for designing a new class of selective estrogen receptor modulators. J Med Chem. 2011 Apr 7. PMID:21473635 doi:10.1021/jm200192y